Business Wire

Eyenuk To Provide Artificial Intelligence (AI) Eye Screening to Thousands of Italians Through Collaboration With Ambrosian Ophthalmic Center in February

Share

Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that it is providing EyeArt® AI Eye Screening as part of the Month of Prevention of Diabetic Retinopathy (DR) and Maculopathy taking place throughout Italy in February. The collaboration between the Ambrosian Ophthalmic Center (CAMO), San Raffaele Hospital and Eyenuk™ is sponsored by the Italian Ministry of Health, the city of Milan and the Italian Ophthalmology Society.

During February, 30 centers across Italy will offer screening for DR using the EyeArt AI Eye Screening System, the most-extensively validated AI technology for autonomous detection of DR, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.

DR is a complication of diabetes and the main cause of vision impairment and blindness among working-age adults. It occurs when high blood sugar levels lead to damage in the blood vessels of the retina, the light-sensitive tissue at the back of the eye. Annual eye screening is recommended for people living with diabetes since DR can progress silently without any perceptible symptoms or vision deterioration.

“Early detection of DR is an important part of managing care for millions of people with diabetes, yet less than half of the people with diabetes see an eye doctor on an annual basis. AI Eye Screening can make early detection of DR more accessible, allowing patients to seek treatment and likely save their vision,” explains Dr. Lucio Buratto, scientific director of CAMO.

The EyeArt AI Eye Screening System is designed to make it possible for any physician to quickly and accurately detect referable DR patients in less than one minute during a diabetic patient’s regular exam. This helps remove the biggest obstacle to annual DR screening and diagnosis: patient compliance. With the EyeArt System, physicians can identify patients with vision-threatening DR in-clinic, in real time, so they can be immediately referred to a vision specialist for treatment to save their sight. The EyeArt System uses AI algorithms to autonomously analyze images of the eye taken with a retinal camera. This advancement can enable timely detection of vision-threatening DR by a nurse or non-specialist and eliminate the need for an eye care expert to carefully grade patient’s retinal images.

VIDEO: See How the EyeArt System Performs Eye Screening for Diabetic Retinopathy

“Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy,” says Kaushal Solanki, CEO of Eyenuk. “We are grateful for this opportunity to partner with these esteemed organizations in Italy to enable early detection of DR, thus advancing our mission with a critical step towards eliminating preventable blindness.”

For more information about the free AI Eye Screenings and the Month of Prevention of Diabetic Retinopathy and Maculopathy, please visit http://www.maculopatie.com/.

About Diabetic Retinopathy (DR)

DR is a complication of diabetes caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). It is a silently progressing disease. At first, DR progresses without any symptoms at all, but eventually it can cause blindness. The condition can develop in anyone with type 1 or type 2 diabetes.i It is estimated that one-third of all patients living with diabetes will develop the blinding disease,ii making it the leading cause of vision loss in working-age adults.iii

About Eyenuk Inc.

Eyenuk Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk’s first product, the EyeArt AI Eye Screening System, is the most extensively validated AI technology for autonomous detection of diabetic retinopathy, validated in real world clinical studies with over 160,000 patient visits and over a million images. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease.

EyeArt has CE marking and has been cleared for sales as a Class IIa medical device by EU and as a Class 2 medical device by Health Canada. In the U.S., the EyeArt® System is limited to investigational use only.

EyeArt® is a registered trademark of Eyenuk Inc.

www.eyenuk.com
media@eyenuk.com

_____________________________________
i https://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/symptoms-causes/syc-20371611
ii Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64. doi: 10.2337/dc11-1909
iii Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature reviewOphthalmic Res. 2012;47:171-188. doi: 10.1159/000329603

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Capwell Communications
Jensie Simkins
jensie@capwellcomm.com
949-999-3303

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Owl Labs: 89% of European Companies Plan on Having a Hybrid Workforce Post-pandemic23.6.2021 02:01:00 EEST | Press release

Research conducted by Owl Labs, which polled 2000 business leaders* based in the UK, Germany, France, and the Nordics** shows that just 11% of business leaders expect their employees to return to the office full-time, indicating a more permanent shift to hybrid working. What’s more, the majority of European organisations (92%) are keen to explore progressive policies post-pandemic including introducing working from anywhere (42%), core working hours (39%), a four-day week (39%), and unlimited holiday (22%). When considering why employers are permanently moving to a more flexible work model, profitability plays an important role. Close to two-thirds (62%) of European business leaders reported that hybrid working makes companies more profitable with Enterprise businesses (1000+ employees) the most likely to think so (73%) versus small and medium-sized companies (55%). As businesses continue to adapt to working in a Covid-19 environment, over a third (39%) of European business leaders ant

Northleaf Appoints Shane Feeney to Lead and Expand Its Well-established Global Secondaries Business22.6.2021 21:00:00 EEST | Press release

Northleaf Capital Partners (Northleaf) today announced that Shane Feeney has joined the firm as Global Head of Secondaries, based in Toronto. In this role, Feeney will oversee all aspects of Northleaf’s secondaries program, building on the firm’s highly successful 18-year track record in global secondary investing and enhancing existing team capabilities as the secondaries market continues to expand rapidly. Feeney most recently served as Senior Managing Director & Global Head of Private Equity at CPP Investments, one of the world’s largest institutional investors with $497.2 billion in assets under management as of March 31, 2021. In this role, Feeney led the teams responsible for CPP Investments’ direct private equity, Asia private equity, private equity funds and secondaries investments. Under Feeney’s leadership, CPP Investments’ private equity program assets under management grew by approximately $73.6 billion. In fiscal 2021, CPP Investments’ private equity program generated a ne

SES Successfully Prices EUR 150 Million Tap of 2026 Eurobond22.6.2021 19:46:00 EEST | Press release

SES S.A. announced today the successful launch and pricing of a tap of its 1.625% Notes due 22 March 2026 in which it has agreed to sell incremental senior unsecured fixed rate notes for a total amount of EUR 150 million. The new notes were priced at 106.665% of their nominal value representing a credit spread of 47bps and a yield-to-maturity of 0.207%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005953/en/ SES Successfully Prices EUR 150 Million Tap of 2026 Eurobond (Photo: Business Wire) SES is rated Baa2 by Moody’s (with negative outlook) and BBB- by Standard & Poor’s (with stable outlook). Proceeds of the issuance will be used for general corporate purposes. BBVA, Deutsche Bank and IMI Intesa Sanpaolo acted as Joint Bookrunners. The settlement is scheduled for 29 June 2021 and application has been made for the notes to be listed on the Luxembourg Stock Exchange. The securities were placed with a broad range of i

Safic-Alcan Extends Its Distribution Agreement With PMC Organometallix to the African Continent22.6.2021 19:35:00 EEST | Press release

Safic-Alcan, a global specialty chemicals distributor, is pleased to announce the extension of its distribution agreement with PMC Organometallix Inc. to the African continent. PMC Organometallix, Inc., a wholly owned subsidiary of PMC Group, N.A., Inc. has expanded its distribution agreement with Safic-Alcan to include the African continent. Effective immediately, Safic-Alcan will serve as an authorized distributor of PMC Organometallix’s FASCAT® catalysts and fine chemicals. FASCAT® catalysts are inorganic and organometallic tin compounds providing optimal conversion and curing characteristics - making these organometallic materials essential in a wide variety of applications. FASCAT® catalysts are used in the manufacture of synthetic lubricants, monomeric and polymeric ester synthesis, automotive e-coat, crosslinking of siloxanes, urethanes and chemical intermediates. “Building on our successful partnership with Safic-Alcan in continental Europe, we are pleased to extend our collabo

In Celebration of World Rainforest Day, 33 Qualified Teams and 9 Judges Announced in $10M XPRIZE Competition to Improve Understandings and Preservation of the Planet’s Rainforests22.6.2021 19:24:00 EEST | Press release

XPRIZE, the global leader in designing and operating incentive competitions to solve humanity’s grand challenges, officially announced today the teams moving forward in the $10M XPRIZE Rainforest aimed at improving our understanding of the rainforest ecosystem. Sponsored by Alana Foundation, the five-year XPRIZE Rainforest is a call-to-action to help save rainforests through the development of transformative, scalable, and affordable technology to autonomously survey and monitor biodiversity in real-time, leading to insights that communicate the health, well-being, and value of standing tropical rainforests. XPRIZE Rainforest is co-developing an inclusive framework throughout all stages of the competition that ensures competing teams co-design and co-create solutions with Indigenous Peoples and local communities as key stakeholders and not just beneficiaries. These 33 teams will now leverage existing and emerging technologies, such as robotics, remote sensing, data analysis, artificial

BourseInside, The New Media Platform That Finds Attractive Investments for Curious Investors22.6.2021 18:08:00 EEST | Press release

On the stock market, small caps continue to outperform. Since 1926, they have posted a performance of 12.1% per year, in contrast to 9.7% for large caps. And yet these so-called "small stocks" have been largely ignored by the stock market. They are rarely covered by analysts, shunned by the mainstream stock-market press and neglected by funds. Nevertheless, they are of great interest to investors, in particular those who have recently taken to investing in the stock market in order to grow their savings (16% increase in investors in 2020). For half of these newcomers, investing in the stock market gives them the opportunity to support the French economy by supporting the growth of our future champions and to channel their savings into a more sustainable and fairer model. In order to further strengthen this link between the French people and the development of our national companies, we decided to create BourseInside, the first web/TV/newsletter media platform, fully dedicated to listed

DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma22.6.2021 17:31:00 EEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the European Commission (EC) has granted marketing authorisation for the expanded use of DARZALEX®▼ (daratumumab) subcutaneous (SC) formulation in two new indications. The first authorisation of these new indications is for the use of daratumumab SC in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adults with newly diagnosed systemic light chain (AL) amyloidosis. This approval makes this daratumumab-based regimen the first approved therapy for AL amyloidosis in Europe. The second authorisation is for the use of daratumumab SC in combination with pomalidomide and dexamethasone (D-Pd) for the treatment of adults with multiple myeloma (MM) who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor, and have

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom